

**SUMMARY OF DECISIONS**

| **Recommendations made by HNY APC subgroups** | **June 2025** |  |
| --- | --- | --- |
| **Approved by: HNY APC** | **2nd July 2025** |
| **Reviewed by: CPC**  NB: HNY APC is a decision-making group. Decisions are submitted to CPC for information. | Scheduled for July meeting |
| **The NHS is legally obliged to fund and resource medicines and treatments recommended by NICE's technology appraisals. When NICE recommends a treatment 'as an option', the NHS must make sure it is available within 90 days (unless otherwise specified) of its date of publication. This means that, if a patient has a disease or condition and the doctor responsible for their care thinks that the technology is the right treatment, it should be available for use, in line with NICE's recommendations.**  For copies of current HNY APC minutes and decisions, please visit <https://humberandnorthyorkshire.org.uk/area-prescribing-committee-apc-minutes-from-meetings/>. | | |

|  |
| --- |
| **DECISIONS WITH A FINANCIAL OR COMMISSIONING IMPACT** |

| **Drug and indication** | **Status and formulary position assigned** | **Notes on decision** | **Cost impact and commissioning / service implications** | **APC decision** |
| --- | --- | --- | --- | --- |
| **Ciclosporin** shared care protocol | Formulary to be updated to reflect that preferred brands are Deximune and Capimune. | National guidance states that ciclosporin should be prescribed by brand name to prevent inadvertent switching.  An updated shared care protocol has been approved by APC pending addition of wording on managing intentional switching of brands. | Expected to be cost saving, by allowing selection of best value product in secondary care and reducing use of the highest cost products in primary care. | Approved |

|  |
| --- |
| **DECISIONS WITHOUT A FINANCIAL OR COMMISSIONING IMPACT** |

| **Drug and indication** | **Status and formulary position assigned** | **Notes on decision** | **Cost impact and commissioning / service implications** | | **APC decision** |
| --- | --- | --- | --- | --- | --- |
| **HNY Unified COPD Formulary and Guidelines** | Medicines assigned a GREEN status:   * Anoro Ellipta 55/22 * Bevespi Aerosphere 7.2/5 * Spiolto Respimat 2.5/2.5 * Ultibro Breezhaler 85/43 * Acetylcysteine * Carbocisteine   Medicines assigned a GREEN with guideline status:   * Trelegy Ellipta 92/55/22 * Trimbow Nexthaler 88/5/9 * Trimbow pMDI 87/5/9 * Trixeo Aerosphere 5/7.2/160 * Azithromycin   Medicines assigned an amber (specialist initiation) status:   * Roflumilast | The Humber and North Yorkshire (HNY) Unified COPD Formulary and Guidelines provide system-wide, evidence-based guidance on the diagnosis and management of COPD | Potential to reduce prescribing costs and improve outcomes through use of single inhaled triple therapy for appropriate patients. Guideline implementation will be supported by the HNY Respiratory Network. | Approved | |
| **Methotrexate SCF V2.0** | No change status or formulary position  Updates to Methotrexate SCF as follows;   * Section 5: Added statement on excluding pregnancy prior to treatment * Section 10: Advice on management of patients who become pregnant clarified. * Section 11: Advice on duration of effective contraception following stopping methotrexate harmonised and aligned with BSR. | Since HNY V1.0 Methotrexate SCF was approved by HNY APC in April 2025, the RDTC have updated the Methotrexate SCF template (27/05/25).  These updates have been incorporated into the Methotrexate HNY V2.0 Methotrexate SCF | No change | Approved | |

|  |
| --- |
| **DECISIONS FOR INFORMATION ONLY** |

| **Drug and indication** | **Rationale / criteria** | **Status and formulary position assigned** | **Notes on decision** | **Cost impact** |
| --- | --- | --- | --- | --- |
| HNY APC minutes – June 2025 |  |  | Approved |  |
| All links to MHRA drug safety updates added to formulary as published. Significant alerts where further action is required are highlighted. | | | | |

HNY APC Professional Secretariat Provided by:

Regional Drug and Therapeutics Centre

16/17 Framlington Place, Newcastle upon Tyne, NE2 4AB

Tel: **0191 213 7855** email: [nuth.hnyapc@nhs.net](mailto:nuth.hnyapc@nhs.net) visit: <https://humberandnorthyorkshire.org.uk/area-prescribing-committee-apc/>

 [@RDTC\_Rx](https://twitter.com/RDTC_Rx)

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES. PATIENT INFORMATION ON MANY TOPICS CAN BE ACCESSED VIA NHS CHOICES